Basic Science Flashcards
exfix
factors inflencing the stiffness of a frame?
number 1 = reduction then diameter of screw
stiffness r to power of 4
anti-thrombotics
TXA: what’s the mechanism of action?
antifibrinolytic
Mechanism:
inhibits conversion of plasminogen to plasmin
prevents fribinolysis
prevents breaking down of clots. it stabilizes clots. Does NOT promote clots
tPA promotos fibrinolysis
anti-coagulation
Know: mechanisms, contraindications, things gone bad
A. Aspirin
B. Lovenox
C. Warfarin
D. Rivaroxaban (Xarelto), Apixaban (Eliquis)
E. Dabigatran
anticoagulation
Aspirin mechanism of action
- inhibits the production of prostaglandins and thromboxanes through irreversible inactivation of the cyclooxygenase enzyme within platelets
- Irreversible binds COX in platelets
thromboxane function
under normal conditions thromboxane is responsible for the aggregation of platelets that form blood clots
prostaglandins function
prostaglandins are local hormones produced in the body and have diverse effects including
the transmission of pain information to the brain
modulation of the hypothalamic thermostat
inflammation
anti-coagulation
Warfarin mechanism of action and reversal, when to stop pre-op?
- Prevents Vit-K gamma carboxylation
II,VII, IX, X & protein C & S
* inhibits vitamin K 2,3-epoxide reductase - reversal Vit K: PO or IV (3 days); FFP immediate
- stop 5 days pre-op
target INR 2-3 for orthopatients
Heparins
Heparin and LMWH (enoxaparin)
inhibits? reversal agent? excreted through?
Heparin: binds and enhances ability of antithrombin III to inhibit factors IIa, III, Xa
LMWH: inhibits Xa and thrombin (IIa); LMWH acts in several sites of the coagulation cascade, with its principal action being inhibition of factor Xa
protamine sulfate
kidneys!
DOACs
2 types: Factor Xa inhibitors and Direct thrombin inhibitors?
Reversals?
- RivaroXaban, Apixaban, edoXaban: direct Xa inhibit. 12hr half line for apixaban. Reversal: AndeXanet alpha
- daBigatran (Pradaxa): direct thrombin (IIa) inhibitor Reversal: Idarucizumab
- Thrombin = IIa
mechanism of action of these drugs can be deduced from the name.
* Rivaro(Identifier)-xa(FactorXa)-ban(inhibitor)
* DaBigatran (Pradaxa): direct thromBin inhibitor
anticoagulants
indirect Factor Xa inhibitor
Fondaparinux: irreversibly binds X thru ATIII
(Indirect Xa inhibitor (works through ATIII))
osteoprogenitor cells: differentiation based on?
Strain and Oxygen.
High strain: fibroblast (think nonunion)
Medium strain, low O2 = chondrocyte
Low strain, High O2 = osteoblast/osteocyte
Bone cells
Osteoblast Development:
* under control of ? signaling?
* 3 key transcription factors
Chondrocyte development:
Adipocyte development
Blasts: Wnt Signaling
Key TF: B-catenin, Runx2, Osx
Chondrocytes: Sox9, “Sox sucks for making bone”
PPARy causes adipocytes (widest, looks fatest)
- Osteoblasts are derived from undifferentiated mesenchymal stem cells, and RUNX2 is the multifunctional transcription factor that directs this process.
- Wnt/Beta-catenin (B-catenin) pathways are involved in osteoblast differentiation.
Osteoblasts
control bone production via 2 receptors:
PTH: ultilizes ? as mediator for signaling, Pulsed PTH has what effect on bone?
Vitamin D
Osteoblasts produce?
PTH: ultilizes adenylyl cyclase as mediator for signaling
Pulsed PTH has anabolic effect on bone
- Osteoblasts produce type I collagen (i.e., bone), alkaline phosphatase, osteocalcin, bone sialoprotein, and RANKL
osteoblasts make bone by producing nonmineralized matrix: Type I collagen, alkaline phosphatase
Osteoclast
inhibit osteoblasts via what messenger?? what is the effect of PTH and Calcitonin on this?
sclerostin:
- produced by osteocytes
- inhibits bone formation
- occurs via Wnt pathway antagonism
- can measure in blood, want low levels if supplementing patient with vitamind D
- PTH: increases sclerostin
- Calcitonin- decrease sclerostin
Former osteoblasts trapped in the matrix they produce
communicate via gap junctions in caliculi
osteoclasts
Osteoclasts are derived from ?.
? is produced by osteoblasts, binds to immature osteoclasts, and stimulates differentiation into active, mature osteoclasts that result in an increase in bone resorption.
Resorb: only ? matrix; occurs at ?; forms ?
how do they bind to bone?
? inhibits bone resorption by binding and inactivating ?
- Osteoclasts are derived from hematopoietic cells in the macrophage lineage.
* RANKL is produced by osteoblasts, binds to immature osteoclasts, and stimulates differentiation into active, mature osteoclasts that result in an increase in bone resorption. - resorb mineralized matrix, at ruffled border, forms howships lacunae
- Bind to bone via: integrins - > vibronectin (sealing zone)
- OPG inhibits bone resorption by binding and inactivating RANKL.
- Osteocytes are former osteoblasts surrounded by newly formed matrix. They are important for control of extracellular calcium and phosphorous concentration, and are less active in matrix production than are osteoblasts.
Osteoclasts bind to bone surfaces by means of integrins (vitronectin receptor), effectively sealing the space below, and then create a ruffled border and remove bone matrix by proteolytic digestion through the lysosomal enzyme cathepsin K.
Osteoclasts disorders:
carbonic anhydrase mutation leads to?
Cathespin K mutation leads to?
CA mutration = OSTEOPETROSIS
Catespin K mutation = pyknodysostosis
osteoclasts are regulated by 2 key molecules produced from osteoblasts?
Osteoprotegerin (OPG): prevents osteoclast activation by inactivating RANKL (osteoprotegrin Protects)
RankL: activates Osteoclastis
osteoclasts regulation
PTH can cause bone resorption via?
Osteoblasts van prevent resorption via?
PTH (receptor on osteoblast) – via RANKL
osteoblast prevents resoprtion via OPG